Pomerantz LLP

Please review this complaint. Click to Contact Us about joining this ACTION >>

Questions? Ask Us

OPKO Health, Inc.

Pomerantz LLP is investigating claims on behalf of investors of  OPKO Health, Inc. ("OPKO" or the "Company").

The investigation concerns whether OPKO and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

On May 18, 2018, OPKO announced the issuance of a draft local coverage determination ("LCD") for the Company's 4Kscore test for prostate cancer.  OPKO advised investors that "[t]he draft LCD is a proposed non-coverage policy for the 4Kscore test for Medicare and, prior to its effectiveness, is subject to a public comment period ending July 5, 2018."  Following this announcement, OPKO's share price fell $0.89, or 18.24%, to close at $3.99 on May 18, 2018.